Business
OrthoPediatrics Corp. Reports Third Quarter 2025 Financial Results
Increased Third Quarter 2025 Revenue 12% Year-over-year, and Increased Adjusted EBITDA by 56% year-over-yearWARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 and Recent Business Highlights Helped over 37,000 children in the third quarter of 20
About this update from Orthopediatrics Corp.
[{"type":"image","alt":"OrthoPediatrics Corp.","displaySize":"","headline":null,"caption":"OrthoPediatrics Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/29d424390c1c4ef384b72b889c10210b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1WUGYhT71wCcQ7.AD2ziQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/29d424390c1c4ef384b72b889c10210b","width":300,"height":96}},"lazy":false},{"type":"text","content":"Increased Third Quarter 2025 Revenue 12% Year-over-year, and Increased Adjusted EBITDA by 56% year-over-year","length":108,"tagName":"p"},{"type":"text","content":"WARSAW, Ind., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2025.","length":292,"tagName":"p"},{"type":"text","content":"Third Quarter 2025 and Recent Business Highlights ","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Helped over 37,000 children in the third quarter of 2025 and approximately 1.3 million children to date","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated new record high total revenue of $61.2 million for the third quarter of 2025, up 12% from $54.6 million in third quarter 2024; domestic revenue increased 14% and international revenue increased 6% in the quarter","length":221,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated total revenue excluding 7D capital sales of $60.7 million for the third quarter of 2025, up 17% from $51.8 million in the third quarter 2024. Domestic total revenue excluding 7D capital sales of $48.2 million for the third quarter of 2025, up 19% from $40.5 million in the prior year period","length":300,"tagName":"p"}]},{"val":[{"type":"text","content":"Grew worldwide Trauma & Deformity revenue 17% and worldwide Scoliosis revenue 4% in the third quarter of 2025 compared to the third quarter of 2024","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased adjusted EBITDA by 56% to $6.2 million in the third quarter of 2025, compared to $4.0 million in the third quarter of 2024","length":132,"ta...